Pfizer announces REFLECTIONS B357-02 study meets main goal

Pfizer Inc. announced last week that its study to assess the safety, efficiency and immunogenicity of PF-06438179 called REFLECTIONS B537-02 has met its primary endpoint.

The Phase 3, multi-national, randomized, double blind, two-arm, parallel group study is designed to evaluate PF-06438179 (infliximab-Pfizer) versus Remicade in combination with methotrexate when administered intravenously to treat patients with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to methotrexate therapy.

The trial, which compared PF-06438179 to Remicade, proved that PF-06438179 showed the same efficiency as the originator product at 14 weeks. The results of the trial were measured by the American College of Rheumatology 20 (ACR20).

Pfizer is developing PF-06438179 to be a possible Remicade biosimilar.